Introduction
Meningiomas arise from the arachnoid lining covering the brain and spinal cord and account for~25% of all primary central nervous system neoplasms (Lantos et al., 1996; Perry et al., 2004) . Although generally slow-growing and benign, these tumors cause significant morbidity by compressing adjacent cranial nerves or blood vessels. They may occur sporadically, or in the familial tumor disorder neurofibromatosis 2 (NF2), which also exhibits schwannomas (Gutmann et al., 1997; Evans et al., 2005) . About 60% of sporadic meningiomas result from biallelic inactivation of the NF2 tumor suppressor gene and consequent inactivation of the merlin protein (Seizinger et al., 1987; Trofatter et al., 1993; Rouleau et al., 1993) . Other genetic aberrations are implicated in the initiation of non-NF2 associated meningiomas and in the progression of benign meningiomas to higher-grade tumors (Collins, 2004; Lamszus, 2004; Perry et al., 2004) .
Merlin is related to ezrin, radixin and moesin (ERM) of the band 4.1 superfamily of integral membrane-cytoskeletal linkers (Trofatter et al., 1993; Rouleau et al., 1993) and is believed to overlap functionally with these proteins, which are essential for regulating many cellular processes including cell shape, motility, membrane transport and signal transduction pathways (GonzalezAgosti et al., 1996; Pelton et al., 1998; Hall, 1998; Tsukita and Yonemura, 1999; Bretscher et al., 2002; McClatchey and Giovannini, 2005) . However, in spite of the wealth of information gained from mouse models (McClatchey and Cichowski, 2001; Gutmann and Giovannini, 2002; Kalamarides et al., 2002) and comparative ERM studies, merlin's growth regulatory mechanisms have not been fully elucidated. Actin-cytoskeletal disruption, cellular overproliferation and loss of cell contact inhibition have been observed in several different cell lines lacking merlin or expressing dominant-negative merlin (Lutchman and Rouleau, 1995; McCartney and Fehon, 1996; Pelton et al., 1998; Morrison et al., 2001; Johnson et al., 2002; Lallemand et al., 2003; Okada et al., 2005) . Conversely, merlin overexpression results in inhibition of many signaling pathways (Gutmann et al., 1999; Lutchman and Rouleau, 1995; Sun et al., 2002; Xiao et al., 2005 
